Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Temelimab (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Multiple sclerosis; Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors GeNeuro Australia
- 13 Jul 2019 Results published in the Clinical Therapeutics
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Jan 2019 Results published in the Media Release